We observed a young patient with slight mental retardation, suffering from drug-resistant tonic-clonic seizures, who presented a status epilepticus (SE), in two separate periods when valproic acid (VPA) was added to the phenobarbital (PB) already being used in the patient's therapy. The VPA-induced SE was characterized by normal plasma levels of antiepileptic drugs (AEDs), normal ammonemia and normal liver function. The case we studied represents the first report on a VPA-induced SE. Furthermore the case confirms that VPA, as well as causing encephalopathy secondary to hyperammonemia, may also provoke a primary involvement of the central nervous system (CNS), specially when used in young epileptic, mentally retarded subjects. In an attempt to explain the paradoxical effect of VPA we hypothesise that the SE could be due to an increase in excitatory activity producing a consequent epileptogenic effect in those subjects with a predisposition for toxic reaction to VPA therapy due to congenital anomalies of neural networks,
INTRODUCTION
The administration of valproic acid (VPA), an antiepileptic drug (AED) often used to control typical absence seizures and generalized tonic-clonic seizures, is sometimes the cause of severe toxic effects which involve the central nervous system (CNS). Many reports emphasize the role of VPA in inducing an encephalopathy characterized by ataxia, stupor and coma***.
In certain conditions VPA produces a paradoxical effect by increasing the number of epileptic seizures3".
The most widely recognized hypothesis is that the encephalopathy is caused by an increase of ammonemia, due to hepatic or renal dysfunction"".
In this study the case of a young epileptic patient is reported. The boy suffered a status epilepticus (SE), with normal plasma levels of the AED, normal ammonemia and normal liver function, in two different periods when VPA was added to phenobarbital (PB), already being used in therapy.
PATIENT REPORT
The patient is a lCyear-old, right-handed boy affected by AED-resistant epileptic seizures. There were no familial neurological diseases, apart from a cousin of his mother who had generalized epileptic seizures during childhood and adolescence. The pregnancy, birth and psychomotor development were normal; until the appearance of the first seizure he had not been affected by any serious illnesses.
The first generalized tonic-clonic seizure occurred at age 6 years; the second seizure appeared 3 months later, after which the boy started taking PB. He did not experience another seizure for 3 years. Between the ages of 9 and 14 years he presented repeated tonic-clonic seizures, averaging one every 3 months. During this period he was taking 100-150 mg of PB a day with plasma levels between 18 and 27 pg/ml.
At the age of 14 years, after a period characterized by frequent tonic-clonic seizures, he was admitted to the Neurological Clinic of the University of Perugia. At the time of admission the neurologi-@ 1998 British Epilepsy Association cal examination was normal, the cognitive function evaluation showed a slight mental retardation and a cranial cerebral tomography (CT) scan did not show any alterations.
In order to control the seizures VPA was associated to a daily PB dose of 4 mgkg with a plasma level of 24 pg/ml. At first a daily VPA dose of 10 mgfkgfday was administered. This was progressively increased over 7 days to a maximum dose of 25 mg/kg/day in three administrations. Approximately 13 days after the start of VPA the clinical picture worsened considerably. The boy started to have axorhizomelic tonic seizures that increased in number until SE was reached.
After 2 days of these conditions, and before suspending VPA, the plasma levels of the AEDs were within the therapeutic range (PB 26, VPA 56 and 69 on an empty stomach and 3 hours after the first administration respectively).
The suspension of VPA led to the complete regression of the tonic seizures in a few days. The boy was discharged with a monotherapy of PB.
Three months later, during another period in hospital because of persistent tonic-clonic seizures, VPA was added to PB following the same procedure of a progressive increase until a maximum dosage of 25 mg/kg/day was reached. Fifteen days after the start of this new trial the boy again suffered several tonic epileptic seizures with the same characteristics as the previous episode. The AED plasma levels, as before, were within the therapeutic range, 64 and 70 kg for VPA and 31 pg for PB.
The epileptic tonic status disappeared completely in the 5 days following the suspension of VPA.
Electroencephalography studies
The boy periodically underwent electroencephalographs (EEGs) from the age of 6 years, a few months after the appearance of the first seizure.
lnterictal EEGs At age 6 and 7 years the EEG showed posterior 9 Hz alpha-rhythm background activity, several posterior slow waves and bilateral, synchronous and symmetric subclinical short spike and wave discharges at 3-4 Hz (Fig. 1) . The EEGs, performed from age 8 to 14 years, showed the same background activity and the same intercritical, paroxysmal anomalies.
Electroclinical findings of status epilepticus
Throughout both the first and the second therapeutic trial with a VPA-PB association, the boy presented a SE expressed by very frequent, short and long axorhizomelic tonic seizures.
The short axorhizomelic seizures, lasting only 2-5 seconds, were more frequent and mainly involved the face, neck and upper limb muscles. The less frequent long axorhizomelic seizures, lasting 15-20 seconds, began in the neck and face muscles and rapidly involved the upper and lower limbs.
As far as the EEG is concerned, in a high-voltage delta background activity, interrupted by isolated spikes and sharp waves on all the derivations, the short tonic seizures (Fig. 2) were characterized by the sudden appearance of a generalized, very rapid, high amplitude activity at about 20 Hz.
In the same background activity, the axorhizomelic long seizures (Fig. 3 ) appeared initially with a sudden flattening of all electrical activity corresponding to the involvement of the axial muscles, followed by rapid activity, increasing in amplitude on all the derivations, corresponding to tonic involvement of the limb muscles.
Metabolic parameters
During both the first and the second tonic SE, many biochemical parameters were evaluated: serum glucose, blood urea nitrogen, prothrombine time, GOT, GPT, )/GT, alkaline phosphatase, CPK, LDH and biliary acids. All the values were found to be normal. At the same time ammonemia monitoring was also performed. During the first trial ammonemia reached maximum values of 38 Fg/dl, while in the second trial it remained between minimum values of 20 kg/d1 and maximum values of 31 Fg/dl (normal values less than 75 pg/dl).
DISCUSSION
In our report we described a case of SE elicited by VPA. Various AEDs can result in an increase in epileptic seizures or elicit new types of seizure1 I. It has already been shown that VPA in particular conditions could worsen epileptic seizures.
Dreifuss et al4 described a SE, attributed to VPAinduced hepatotoxicity, in some patients undertaking VPA therapy associated with other AEDs. Bohan et al5 reported a SE and liver damage in an epileptic child treated with valproate. An unexplainable absence status was reported by Jeavons et al3 in five patients taking an association of VPA-clonazepam.
A.S. a.6 24.5.86 50 mVJ I sec. The VPA-induced increase of epileptic seizures has been related to hyperammonemia with or without hepatic damage.
During VPA therapy, some young, metabolically susceptible patients could present hyperammonemia and hepatic lesions", necrosis and microvescicular steatosis, caused by an error of the mytochondrial l3-oxidation .
I3 Valproic-acid-' Induced hyperammonemia without hepatic damage could be explained by an increase of propionate in the blood, which inhibits the carbamyl phosphate synthetase I activity, leading to an increase of ammonium'". An alternative hypoth- esis is that the VPA-induced increase of renal glutaminase activity is responsible for the increase of ammonium in the renal vascular system and in the genera1 artery system which is too great for the liver to correct'5.
Other studies have demonstrated that VPA can produce a primary involvement of the CNS. Sackellares et ~1'~ demonstrated in four epileptic patients that the stupor induced by VPA, in association with other AEDs, was accompanied by normal ammonemia and normal liver-function values. Pakalnis et a/l7 indicated that in some young epileptics, showing slight or mild mental retardation, the addition of VPA to pre-existing AEDs was the cause of an acute encephalopathy without signs of hepatic dysfunction, with normal ammonemia and plasma levels of AEDs in the therapeutic range.
The case we have described is the first report revealing that VPA could induce a SE without hyperammonemia or hepatic damage.
The young patient showed slight mental retardation and suffered from generalized epilepsy expressed by tonic-clonic seizures that were not controlled by the therapy.
The clinical-EEG characteristics of VPA-induced SE, the value of ammonium (checked several times) below pathological levels and the absence of any marker of hepatic damage, lead us to believe that VPA was the cause of a primary involvement of the CNS.
It of axial
The action mechanism of VPA is still unclear. Valproic acid seems to increase the levels of GABA in the CNS by inhibition of y-aminobutyric acid (GABA) degradation'* and may increase the GABA postsynaptic responses. Furthermore the mechanism through which the VPA as well as other AEDexacerbate seizures is unknown' ' .
Several hypotheses have been proposed to explain the paradoxical effect of VPA involving GABA"* '9-2' or excitatory aminoacids (EAA)22,23 transmission.
This drug could induce an increase of the excitatory transmission in some mentally retarded subjects with possible congenital anomalies of complex neural networks.
The increased activation of EAA receptors, particularly n-methyl-d-aspartate NMDA, could lead to an excitotoxic and epileptogenic effect.
It seems that mental retardation may play an important role in SE induction in the presence of VPA therapy. Both in our case and in those described by Pakalnis", metabolic, enzymatic and malformative disorders that could confirm the hypothesis of a predisposition for a toxic reaction to VPA therapy have not been found.
Further studies of the molecular involvement of mental retardation and molecular modifications of the receptors are being carried out24 and, in the future, we should be able to explain the mechanisms that are still unclear.
